AI Engines For more Details: Perplexity Kagi Labs You
Allergic Conditions: Cyproheptadine hydrochloride is used to relieve symptoms associated with allergic conditions such as hay fever (allergic rhinitis), allergic conjunctivitis, and allergic skin reactions (urticaria or hives). It works by blocking the effects of histamine, a substance released by the body during allergic reactions, thereby reducing symptoms such as sneezing, itching, watery eyes, and skin rash.
Appetite Stimulation: Cyproheptadine hydrochloride is also used off-label as an appetite stimulant, particularly in individuals with poor appetite or weight loss due to medical conditions such as cancer, HIV/AIDS, or cystic fibrosis. It has been shown to increase appetite and promote weight gain by antagonizing serotonin receptors in the hypothalamus, which regulates appetite and food intake.
Migraine Prevention: Cyproheptadine hydrochloride may be used in the prevention of migraines, particularly in individuals who do not respond to or cannot tolerate other migraine preventive medications. It is thought to exert its migraine-preventive effects through its antiserotonin and antihistamine properties, as well as its ability to block certain serotonin receptors involved in migraine pathophysiology.
Serotonin Syndrome: Cyproheptadine hydrochloride may be used as an antidote or supportive treatment for serotonin syndrome, a potentially life-threatening condition characterized by excessive serotonin levels in the body. It works by blocking serotonin receptors and reducing serotonin activity, helping to alleviate symptoms such as hyperthermia, agitation, confusion, tremor, and neuromuscular hyperactivity associated with serotonin syndrome.
Cyclic Vomiting Syndrome (CVS): Cyproheptadine hydrochloride has been used off-label in the treatment of cyclic vomiting syndrome (CVS), a disorder characterized by recurrent episodes of severe vomiting and nausea separated by symptom-free intervals. It is thought to exert its therapeutic effects by blocking serotonin receptors and reducing the frequency and severity of vomiting episodes in individuals with CVS.
Dosage and Administration: Cyproheptadine hydrochloride is typically administered orally in the form of tablets or syrup. The dosage and frequency of administration depend on the specific medical condition being treated, the severity of symptoms, and the individual patient's response to treatment. It is important to follow the dosage instructions provided by the healthcare provider and to take cyproheptadine hydrochloride as directed to achieve optimal therapeutic outcomes.
Side Effects: Common side effects of cyproheptadine hydrochloride may include drowsiness, dizziness, dry mouth, blurred vision, constipation, and urinary retention. Rare but serious side effects may include allergic reactions, cardiovascular effects (such as palpitations or arrhythmias), and central nervous system effects (such as confusion or hallucinations). Patients should be monitored for side effects during cyproheptadine hydrochloride therapy, and treatment should be adjusted as needed based on individual response and tolerance.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.5 | 0.5 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 3.7 | 0.6 | 5.17 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2 | 1.7 | 0.18 |
| Allergies | 4.7 | 2.1 | 1.24 |
| Allergy to milk products | 1.5 | 1 | 0.5 |
| Alopecia (Hair Loss) | 1.3 | 1.3 | |
| Alzheimer's disease | 4.6 | 4.3 | 0.07 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.4 | 0.6 | 4.67 |
| Ankylosing spondylitis | 3.6 | 0.6 | 5 |
| Anorexia Nervosa | 1.1 | 2.4 | -1.18 |
| Antiphospholipid syndrome (APS) | 0.8 | 0.8 | |
| Asthma | 4.5 | 2.8 | 0.61 |
| Atherosclerosis | 1.1 | 1.7 | -0.55 |
| Atrial fibrillation | 3.4 | 2 | 0.7 |
| Autism | 7.9 | 8.2 | -0.04 |
| Autoimmune Disease | 0.6 | 0.8 | -0.33 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.6 | 0.6 | |
| Bipolar Disorder | 1 | 1.4 | -0.4 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Cancer (General) | 0.6 | 1.4 | -1.33 |
| Carcinoma | 2.9 | 2.3 | 0.26 |
| Celiac Disease | 2.1 | 3.6 | -0.71 |
| Cerebral Palsy | 1.6 | 1 | 0.6 |
| Chronic Fatigue Syndrome | 3.4 | 5.9 | -0.74 |
| Chronic Kidney Disease | 3.2 | 2.5 | 0.28 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1 | 1.7 | -0.7 |
| Chronic Urticaria (Hives) | 0.6 | 1.3 | -1.17 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 1 | -0.43 |
| Cognitive Function | 2.5 | 1.4 | 0.79 |
| Colorectal Cancer | 4.9 | 2 | 1.45 |
| Constipation | 1.2 | 0.7 | 0.71 |
| Coronary artery disease | 0.9 | 2.7 | -2 |
| COVID-19 | 8.6 | 10.3 | -0.2 |
| Crohn's Disease | 6.3 | 6 | 0.05 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.3 | -1.3 | |
| deep vein thrombosis | 1 | 1.1 | -0.1 |
| Denture Wearers Oral Shifts | 1 | 1 | |
| Depression | 8.9 | 8.5 | 0.05 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 0.6 | 1 | -0.67 |
| Endometriosis | 2.3 | 1.7 | 0.35 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 2 | 2.8 | -0.4 |
| erectile dysfunction | 0.3 | 0.3 | 0 |
| Fibromyalgia | 3.4 | 2 | 0.7 |
| Functional constipation / chronic idiopathic constipation | 4 | 3.1 | 0.29 |
| gallstone disease (gsd) | 1.7 | 1.3 | 0.31 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.2 | 0.9 | 0.33 |
| Generalized anxiety disorder | 1.8 | 2.2 | -0.22 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.4 | 0.8 | 0.75 |
| Graves' disease | 1.6 | 3 | -0.88 |
| Gulf War Syndrome | 0.7 | 2.1 | -2 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 2.9 | 1.4 | 1.07 |
| Heart Failure | 2.5 | 2 | 0.25 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 0.5 | 0.3 | 0.67 |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.6 | -1 |
| hyperglycemia | 1.3 | 2.2 | -0.69 |
| Hyperlipidemia (High Blood Fats) | 1 | 0.3 | 2.33 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 4.3 | 4.6 | -0.07 |
| Hypothyroidism | 0.5 | 1 | -1 |
| Hypoxia | 2.1 | 0.3 | 6 |
| IgA nephropathy (IgAN) | 1.3 | 4.1 | -2.15 |
| Inflammatory Bowel Disease | 5.6 | 7.3 | -0.3 |
| Insomnia | 2 | 3.2 | -0.6 |
| Intelligence | 1.2 | 0.4 | 2 |
| Intracranial aneurysms | 0.9 | 0.6 | 0.5 |
| Irritable Bowel Syndrome | 5.8 | 5.6 | 0.04 |
| ischemic stroke | 2.3 | 1.1 | 1.09 |
| Liver Cirrhosis | 5.4 | 4.2 | 0.29 |
| Long COVID | 6.3 | 6.8 | -0.08 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.4 | 1.3 | -2.25 |
| Mast Cell Issues / mastitis | 0.3 | 0.6 | -1 |
| ME/CFS with IBS | 0.6 | 1.7 | -1.83 |
| ME/CFS without IBS | 1.2 | 1.9 | -0.58 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.3 | 1 | 0.3 |
| Metabolic Syndrome | 5.5 | 7 | -0.27 |
| Mood Disorders | 8.9 | 7.6 | 0.17 |
| multiple chemical sensitivity [MCS] | 1.1 | 0.1 | 10 |
| Multiple Sclerosis | 5.6 | 4.8 | 0.17 |
| Multiple system atrophy (MSA) | 1.1 | 0.4 | 1.75 |
| myasthenia gravis | 0.3 | 0.5 | -0.67 |
| neuropathic pain | 0.3 | 3 | -9 |
| Neuropathy (all types) | 1.2 | 1.6 | -0.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.9 | 4.8 | -0.23 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 8.1 | 6.6 | 0.23 |
| obsessive-compulsive disorder | 4.4 | 3.5 | 0.26 |
| Osteoarthritis | 1.8 | 1.3 | 0.38 |
| Osteoporosis | 1.4 | 1.9 | -0.36 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 6.6 | 5.6 | 0.18 |
| Polycystic ovary syndrome | 4.5 | 2.3 | 0.96 |
| Postural orthostatic tachycardia syndrome | 0.6 | -0.6 | |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.2 | 0 |
| Primary sclerosing cholangitis | 1.9 | 1.6 | 0.19 |
| Psoriasis | 2.7 | 3.5 | -0.3 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.1 | 3.9 | 0.56 |
| Rosacea | 0.3 | 0.5 | -0.67 |
| Schizophrenia | 5.6 | 3 | 0.87 |
| scoliosis | 0.3 | 0.6 | -1 |
| Sjögren syndrome | 2.4 | 2.7 | -0.13 |
| Sleep Apnea | 1.6 | 1.5 | 0.07 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.3 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.2 | 0.6 | 1 |
| Stress / posttraumatic stress disorder | 2.6 | 3.3 | -0.27 |
| Systemic Lupus Erythematosus | 2.6 | 2 | 0.3 |
| Tic Disorder | 1.2 | 1.5 | -0.25 |
| Tourette syndrome | 1.3 | 0.3 | 3.33 |
| Type 1 Diabetes | 3.1 | 3.3 | -0.06 |
| Type 2 Diabetes | 7 | 6.6 | 0.06 |
| Ulcerative colitis | 4 | 6.4 | -0.6 |
| Unhealthy Ageing | 3.9 | 2.9 | 0.34 |
| Vitiligo | 1.9 | 1.6 | 0.19 |
